Aspira Women's Health Inc. Announces Receipt of Delisting Notification from Nasdaq
Aspira Women's Health (NASDAQ:AWH) has received a delisting notification from Nasdaq on April 15, 2025. The company's shares will be suspended from trading on Nasdaq effective April 17, 2025, due to non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining a minimum stockholders' equity of $2.5 million for continued listing on the Nasdaq Capital Market.
Following the suspension, AWH's common stock is expected to transition to trading on OTC markets under the same symbol 'AWH'. The company, which focuses on developing gynecologic disease diagnostic tools, will no longer maintain its Nasdaq listing status.
Aspira Women's Health (NASDAQ:AWH) ha ricevuto una notifica di esclusione dalla quotazione da parte del Nasdaq il 15 aprile 2025. Le azioni della società saranno sospese dalla negoziazione sul Nasdaq a partire dal 17 aprile 2025, a causa della mancata conformità alla regola di quotazione Nasdaq 5550(b)(1), che richiede di mantenere un patrimonio netto minimo di 2,5 milioni di dollari per continuare la quotazione nel Nasdaq Capital Market.
Dopo la sospensione, le azioni ordinarie di AWH dovrebbero passare alla negoziazione sui mercati OTC con lo stesso simbolo 'AWH'. L'azienda, specializzata nello sviluppo di strumenti diagnostici per malattie ginecologiche, non manterrà più lo status di società quotata al Nasdaq.
Aspira Women's Health (NASDAQ:AWH) ha recibido una notificación de exclusión de Nasdaq el 15 de abril de 2025. Las acciones de la compañía serán suspendidas de negociación en Nasdaq a partir del 17 de abril de 2025, debido al incumplimiento de la norma de listado Nasdaq 5550(b)(1), que exige mantener un patrimonio neto mínimo de 2,5 millones de dólares para continuar en el Nasdaq Capital Market.
Tras la suspensión, se espera que las acciones ordinarias de AWH pasen a cotizar en mercados OTC bajo el mismo símbolo 'AWH'. La empresa, que se centra en el desarrollo de herramientas diagnósticas para enfermedades ginecológicas, dejará de mantener su estatus de cotización en Nasdaq.
Aspira Women's Health (NASDAQ:AWH)는 2025년 4월 15일 나스닥으로부터 상장폐지 통보를 받았습니다. 회사의 주식은 2025년 4월 17일부터 나스닥에서 거래가 정지되며, 이는 나스닥 상장 규정 5550(b)(1)을 준수하지 못했기 때문인데, 해당 규정은 나스닥 캐피털 마켓에 계속 상장되기 위해 최소 250만 달러의 주주 자본을 유지할 것을 요구합니다.
거래 정지 후 AWH의 보통주는 동일한 심볼 'AWH'로 OTC 시장에서 거래될 것으로 예상됩니다. 여성 생식기 질환 진단 도구 개발에 주력하는 이 회사는 더 이상 나스닥 상장 지위를 유지하지 않게 됩니다.
Aspira Women's Health (NASDAQ:AWH) a reçu une notification de radiation du Nasdaq le 15 avril 2025. Les actions de la société seront suspendues de la négociation sur le Nasdaq à compter du 17 avril 2025, en raison du non-respect de la règle de cotation Nasdaq 5550(b)(1), qui exige de maintenir un fonds propres minimum de 2,5 millions de dollars pour rester cotée sur le Nasdaq Capital Market.
Suite à cette suspension, les actions ordinaires d'AWH devraient être transférées sur les marchés OTC sous le même symbole 'AWH'. L'entreprise, spécialisée dans le développement d'outils de diagnostic des maladies gynécologiques, ne conservera plus son statut de société cotée au Nasdaq.
Aspira Women's Health (NASDAQ:AWH) hat am 15. April 2025 eine Mitteilung über die Delistung vom Nasdaq erhalten. Die Aktien des Unternehmens werden ab dem 17. April 2025 an der Nasdaq vom Handel ausgesetzt, da die Nasdaq-Listing-Regel 5550(b)(1) nicht eingehalten wurde, die ein Mindestaktionärskapital von 2,5 Millionen US-Dollar für die fortgesetzte Notierung am Nasdaq Capital Market vorschreibt.
Nach der Aussetzung wird erwartet, dass die Stammaktien von AWH unter demselben Symbol 'AWH' an den OTC-Märkten gehandelt werden. Das Unternehmen, das sich auf die Entwicklung diagnostischer Instrumente für gynäkologische Erkrankungen spezialisiert hat, wird seinen Nasdaq-Status nicht mehr beibehalten.
- None.
- Delisting from Nasdaq due to failure to maintain minimum $2.5M stockholders' equity requirement
- Downgrade to OTC markets trading, indicating potential reduced market visibility and liquidity
- Non-compliance with major exchange listing requirements suggests financial difficulties
SHELTON, CT / ACCESS Newswire / April 16, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of
Upon suspension of the trading of its Common Stock on Nasdaq, the Company expects that its Common Stock will begin trading under its existing symbol "AWH" on markets operated by OTC.
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the SEC, including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Investors@aspirawh.com
SOURCE: Aspira Women's Health
View the original press release on ACCESS Newswire
FAQ
Why is Aspira Women's Health (AWH) being delisted from Nasdaq?
When will AWH stock be suspended from trading on Nasdaq?
Where will Aspira Women's Health stock trade after Nasdaq delisting?
What are the implications of AWH moving from Nasdaq to OTC markets?
